Zachary Rapp is the Co-Founder and CEO of Sigma Genetics, an intracellular delivery company developing multiple non-viral modalities to power next-generation cell & gene therapies, vaccines, and biomanufacturing. Its flagship platform, the Magnetoporator™, uses pulsed magnetic fields to achieve high-efficiency, non-toxic gene delivery across diverse cell types. Under Zach’s leadership, Sigma has raised over $3.5M, including $1.67M in non-dilutive funding from the Andy Hill CARE Fund and the U.S. Department of Defense, and forged partnerships with Seattle Children’s Research Institute, the U.S. Air Force, and Bloodworks Research Institute. Previously, Zach was Director of Business Development at Altoida Inc., where he supported the company’s FDA and CE designations, led pharma partnerships, and expanded clinical use of its digital biomarker platform across U.S. Alzheimer’s Disease Research Centers (ADRCs). He began his career in oncology and gene therapy research at Columbia University and Mount Sinai, and has co-authored publications in Science, Cell Reports, Surgery, F1000 Research, and Forbes. Zach holds an M.A. in Biotechnology from Columbia University and a Certificate in Venture Capital & Early-Stage Investing from UC Berkeley School of Law.
